Drugs / NaHCO3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable2 trials | ||||||
| — | NCT03818126 | Jul 2016 → Jun 2018 | aortic valve disorder, ischemic disease | Pawel Buszman | Completed | No outcome recorded |
| — | NCT06046924 | Jun 1996 → Nov 2006 | chronic kidney disease, hypertensive disorder | Donald Wesson | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02483143 Comparator | Feb 2014 → Feb 2015 | pulmonary embolism | Karadeniz Technical University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NaHCO3 | “The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml).” NCT03818126 ↗ |
| Route | Intravenous | “The groups received 3 mL/kg intravenous (IV) NAC+NS or NaHCO3 +NS solution or NS alone 1 hour before CTPA and 1 mL/kg IV per hour for a minimum of 6 hours after CTPA.” PMID 27411777 ↗ Sep 2016 |